Skye Bioscience Inc
SKYE
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.75M
Close$
$1.13
37.2% downside
Current Fair Value
37.2% downsideOvervalued by 37.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.75 Million |
|---|---|
| Enterprise Value | $-279,078.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-11.28 |
| Beta | 2.9 |
| Outstanding Shares | 4,960,183 |
Return
| Return on Equity | 10153.20% |
|---|---|
| Return on Assets | -457.62% |
| Return on Invested Capital | -1059.12% |
Valuation & Multiples
| P/E Ratio | -0.17 |
|---|---|
| PEG | 0.45 |
| Price to Sales | - |
| Price to Book Ratio | -1.8 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.05 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.13 |
| Debt to Equity | -0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-2.04
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.24
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3995▼ 112.99% |
|---|---|
| Total Calls | 88,600▲ 126.60% |
| Total Puts | 35,400▼ 40.80% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 40.39%▼ 0.26% |
|---|---|
| Total Invested | $11.11M▲ 12.07% |
| Investors Holding | 45▲ 5.00% |
ESG Score
No data
About Skye Bioscience Inc
11 employees
CEO: Brian Murphy nemus bioscience is a publicly traded, life-science biotech company, developing regulatory-approved, cannabinoid-based therapies, for a spectrum of diseases, especially those of unmet medical need.